Hypoxic-ischemic encephalopathy is brain injury caused by a newborn being deprived of oxygen and blood flow around the time of birth, and it remains one of the leading causes of neonatal death and lifelong disability worldwide. It is also one of the few areas where citicoline has been tested in randomized trials with a placebo group. Understanding what those trials actually establish requires understanding one piece of context that changes everything about how they should be read: who was eligible to be in them.
Nothing here is medical advice. Citicoline is not approved by the FDA to diagnose, treat, cure, or prevent hypoxic-ischemic encephalopathy or any other condition. The research described here used intravenous citicoline given to newborns in neonatal intensive care units. Nothing in it applies to giving supplements to an infant, which should never be done without explicit pediatrician direction.
Key Takeaways
- Two randomized trials exist, together enrolling about 150 newborns. One used a placebo group; the more recent one did not[1][2]
- Both used intravenous citicoline in a neonatal intensive care unit, 10 mg/kg every 12 hours in the placebo-controlled trial[1]
- The critical eligibility detail: the placebo-controlled trial enrolled neonates who were not candidates for therapeutic cooling, the established standard of care[1]
- Reported results were meaningful, including 2 versus 11 neonates with seizures after discharge and better neurodevelopment at 9 and 12 months[1]
- A third study frequently cited as support was an uncontrolled observation of 20 newborns with no comparison group at all[3]
- In one trial citicoline was the comparator arm and lost, performing worse than monosialoganglioside across apoptotic, neurological, and oxidative stress markers[4]
Why Cooling Changes How These Trials Should Be Read
Therapeutic hypothermia, cooling a newborn’s body temperature for about 72 hours, is the established treatment for moderate to severe hypoxic-ischemic encephalopathy in high-income settings. It is the benchmark any new neuroprotective agent has to be positioned against, either as an addition to cooling or as an alternative where cooling is not possible.
The larger citicoline trial states its eligibility criterion plainly: it enrolled 80 neonates with moderate to severe hypoxic-ischemic encephalopathy who were not candidates for therapeutic cooling[1]. That is not a footnote. It defines the question the trial answered, which was whether citicoline helps babies who cannot receive the standard treatment, not whether citicoline adds anything to it.
This framing runs through the wider field. A 2025 systematic review and meta-analysis looked specifically at pharmacologic neuroprotective agents for perinatal asphyxia in low-income and lower-middle-income countries, explicitly because the effectiveness of therapeutic hypothermia remains limited in those settings. It included 12 randomized trials covering 1,008 neonates, and its review protocol excluded therapeutic hypothermia entirely[5]. Citicoline belongs to a research program aimed at settings where cooling is unavailable or unsafe.
The Placebo-Controlled Trial
Eighty neonates with moderate to severe hypoxic-ischemic encephalopathy were randomized into two groups of 40. The treatment group received citicoline 10 mg/kg intravenously every 12 hours for four weeks plus supportive measures. The control group received placebo and the same supportive measures. Assessments covered duration of mechanical ventilation, need for inotropes, seizure type, frequency and duration, and length of NICU stay. Cranial ultrasound and brain MRI were performed on every neonate after four weeks, and all infants were followed for neurodevelopmental outcomes at 3, 6, 9, and 12 months[1].
That is a considerably better design than most of what appears in the citicoline literature. There is a placebo arm. There is imaging read after the treatment period. And there is a full year of neurodevelopmental follow-up, which is the outcome that actually matters to a family, as opposed to a biomarker or a discharge date.
The results were positive across those endpoints. Significantly fewer neonates had seizures after discharge in the citicoline group, 2 compared with 11 in the control group. Cranial ultrasound and MRI findings at four weeks were significantly better in the treatment group. Neurodevelopmental outcome showed significant improvement at 9 and 12 months, and there was a statistically significant reduction in seizure duration[1].
The seizure difference is the most concrete of these. Post-discharge seizures are a hard, countable event that families and clinicians notice, and 2 against 11 is a large gap in a trial of this size. Imaging read at four weeks is likewise less susceptible to expectation than a bedside clinical rating.
The 2026 Trial Was Smaller and Did Not Use a Placebo
A second randomized trial, conducted at a military hospital in Rawalpindi, Pakistan between 2024 and 2025, enrolled 70 neonates with moderate or severe hypoxic-ischemic encephalopathy graded by Sarnat staging. They were allocated by simple randomization into two equal groups. The citicoline group received citicoline in addition to routine care; the control group received routine care only[2].
The reported results were shorter NICU stay, 6.23 days against 8.46 days, and significantly earlier establishment of the suck and Moro reflexes[2]. The authors described this as demonstrating neuroprotective effects.
Two limitations are worth stating directly. First, as in the pediatric cardiac arrest work, the control group received routine care with no placebo, so nobody was blinded, and reflex establishment and discharge timing are both clinician-determined. Second, and more important here, these are short-term outcomes only. Suck reflex and length of stay are not the endpoints that matter for hypoxic-ischemic encephalopathy. What matters is cerebral palsy, cognitive impairment, epilepsy, and developmental delay measured at 18 to 24 months or later. This trial did not report those.
The Pilot Study Cited as Support Has No Control Group
A 2021 observational cohort is frequently included in lists of evidence for citicoline in birth asphyxia. It was conducted at the neonatal intensive care units of two military hospitals and enrolled 20 newborns with moderate to severe hypoxic-ischemic encephalopathy, all of whom received intravenous citicoline. One baby died and 19 were discharged home after oral feeding was established. The authors described citicoline as promising[3].
There is no control group, no randomization, and no blinding, and the authors present it as a pilot project rather than as evidence of efficacy. With 20 infants and no comparison, the study cannot distinguish citicoline from the natural course of the condition combined with good neonatal intensive care. Nineteen of 20 surviving to discharge is not interpretable without knowing what would have happened otherwise, and this design cannot tell us. It belongs in the record as a safety and feasibility observation, not as support for benefit.
The Trial Where Citicoline Was the Losing Arm
One study inverts the usual framing and is more informative for it. Researchers randomized 90 newborns with hypoxic-ischemic encephalopathy into two groups of 45. On top of conventional treatment, one group received monosialoganglioside and the other received citicoline. Both were treated for 10 days, and serum apoptotic factors, neurological function indices, and oxidative stress markers were compared[4].
Citicoline was the comparator, and it lost on every measured axis. After treatment, apoptotic and injury markers were lower in the monosialoganglioside group, and protective and growth factor markers were higher, all at p below 0.001. The authors concluded that monosialoganglioside effectively improves these indices and is worthy of promotion and application[4].
Two caveats keep this from being a verdict. The endpoints are all blood biomarkers rather than clinical or developmental outcomes, and there was no untreated arm, so it establishes relative rather than absolute performance. Still, it is a useful corrective. In head-to-head comparison against another neuroprotective agent in the same population, citicoline was the weaker option on the markers measured. Studies in which a compound serves as the control arm rarely make it into marketing material about that compound.
The Animal Work Behind It
The preclinical basis includes a neonatal rabbit model in which hypoxic-ischemic brain damage was induced by occluding both uterine arteries for eight minutes. Groups of six received piracetam at 100 mg/kg, citicoline at 250 mg/kg, both, or neither. Neuronal destruction rates in the hippocampus were 4 percent in unhypoxic controls, 45 percent in untreated hypoxic animals, 37.5 percent with piracetam, 12.5 percent with citicoline, and 20 percent with both[6].
Citicoline outperformed piracetam and, notably, outperformed the combination, so adding piracetam made the result worse rather than better. The authors state their own limitation clearly, that experimental studies on larger populations are needed, and six animals per group is a small sample for the size of the differences reported[6].
As with the spinal cord literature, the dose does not transfer. 250 mg/kg in a neonatal rabbit is not a milligram figure that maps onto anything a person buys, and the drug was given by injection.
Where This Actually Leaves Things
The honest summary is more encouraging than for most citicoline indications and still well short of established. There is a placebo-controlled randomized trial with 12-month neurodevelopmental follow-up reporting benefit, which is a real result and better evidence than exists for citicoline in several conditions it is more commonly marketed for. There is also a second, weaker randomized trial pointing the same direction on short-term measures, an uncontrolled pilot that adds little, and a head-to-head study where citicoline lost to a different agent on biomarkers.
What is missing is replication by an independent group, larger numbers, and follow-up at 18 to 24 months, which is the standard horizon for neurodevelopmental outcomes in this condition. The 2025 systematic review described neurodevelopmental data across this whole class of agents as generally favorable but limited, with most studies conducted in Asia and only one from Africa[5]. Citicoline was one of several agents evaluated, alongside magnesium sulphate, melatonin, topiramate, and erythropoietin, and magnesium sulphate accounted for the majority of the included studies[5].
For a parent reading this, the practical implications are narrow but clear. This is a hospital treatment decision made by neonatologists in the first hours and days of life, not a consumer decision. If a newborn is a candidate for therapeutic cooling, cooling is the treatment with the strongest evidence, and the citicoline trials were conducted in babies who could not receive it. Nothing in this literature suggests giving a supplement to an infant at home, and infant supplementation of any kind should only ever follow explicit pediatrician direction.
Frequently Asked Questions
Does citicoline help newborns with brain injury from oxygen loss?
Two randomized trials report benefit. The stronger one, with 80 neonates and a placebo group, found fewer seizures after discharge, better cranial ultrasound and MRI findings at four weeks, and better neurodevelopmental outcomes at 9 and 12 months. It has not been independently replicated, and both trials come from a small number of centers.
Why does therapeutic cooling matter to these results?
Because the placebo-controlled trial specifically enrolled neonates who were not candidates for therapeutic cooling, the established standard of care. The trial therefore answers whether citicoline helps babies who cannot be cooled, not whether it adds anything for babies who can be. Much of this research targets settings where cooling is unavailable.
What dose was used?
In the placebo-controlled trial, citicoline 10 mg/kg intravenously every 12 hours for four weeks, given in a neonatal intensive care unit alongside standard supportive care. This is an intravenous hospital protocol and has no relationship to an oral supplement.
Was there a study where citicoline did worse?
Yes. In a 90-newborn comparison against monosialoganglioside, citicoline was the comparator arm and performed worse on serum apoptotic factors, neurological function indices, and oxidative stress markers, all at p below 0.001. The endpoints were blood biomarkers rather than clinical outcomes, and there was no untreated group.
Is the 20-newborn pilot study good evidence?
No. It was an observational cohort with no control group, no randomization, and no blinding, in which all 20 newborns received citicoline and 19 were discharged home. Without a comparison group it cannot separate the drug from the natural course of the condition plus intensive care. The authors present it as a pilot project.
Should I give citicoline to my baby?
No, not on the basis of this research. Every study described here delivered citicoline intravenously to critically ill newborns in an intensive care unit. None tested an oral supplement in an infant, and infant supplementation of any kind should only ever follow explicit direction from a pediatrician.
References
- Salamah A, et al. Citicoline in hypoxic ischemic encephalopathy in neonates: a randomized controlled trial. Italian Journal of Pediatrics (2023). PMID 37173784
- Nawaz A, et al. Role of Citicoline in Neonates with Hypoxic-Ischaemic Encephalopathy. Journal of the College of Physicians and Surgeons Pakistan (2026). PMID 42563339
- Khushdil A, et al. Role of Citicoline in Treatment of Moderate to Severe Birth Asphyxia: A Pilot Project. Journal of the College of Physicians and Surgeons Pakistan (2021). PMID 34794300
- Liang X, et al. Comparative Effects of Monosialoganglioside versus Citicoline on Apoptotic Factor, Neurological Function and Oxidative Stress in Newborns with Hypoxic-Ischemic Encephalopathy. Journal of the College of Physicians and Surgeons Pakistan (2019). PMID 30925953
- Ayeni OA, et al. Pharmacologic neuroprotective agents for the treatment of perinatal asphyxia in low-income and lower-middle-income countries: A systematic review and meta-analysis of randomised controlled trials. PLoS One (2025). PMID 41343532
- Ebrahimi M, et al. Comparison of the Effects of Citicoline and Piracetam on Hypoxic-ischemic Brain Damage in Neonatal Rabbits. Iranian Journal of Child Neurology (2022). PMID 35222659
These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease. This article is for informational purposes only and is not a substitute for professional medical advice. As an Amazon Associate we earn from qualifying purchases.
These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.
